HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line.

AbstractBACKGROUND:
The skeleton is the most common site of prostate cancer metastasis, which often results in osteoblastic lesions. The role of transforming growth factor-beta (TGFβ) signaling in prostate cancer-induced osteoblastic metastasis is not clear. We investigated the role of TGFβ signaling in prostate cancer-induced bone metastasis using a novel human prostate cancer cell line, PacMetUT1.
METHODS:
We injected PacMetUT1/Luc-GFP cells in male nude mice by intracardiac and intratibia injections and then investigated the effect of TGFβ signaling abrogation on osteoblastic tumor growth and incidence in vivo by using fluorescence and bioluminescence imaging analysis and quantifying bone and tumor volume by histomorphometry analysis. Osteoclasts were counted using TRAP assay.
RESULTS:
Osteoblastic bone metastasis in skull, rib, and femur was detected after 10-16 weeks of intracardiac injection of the PacMetUT1 cells. Stable knockdown of TGFβ1 with an shRNA resulted in decreased tumor incidence and bone formation when the cells were directly injected into the tibiae. Systemic administration of either a small inhibitor of TGFβ type I receptor kinase or a pan TGFβ binding protein (BG(E) RII) also decreased bone tumor growth and osteoblastic bone formation in vivo after 7 weeks of treatment.
CONCLUSIONS:
Our results for the first time indicate that blockade of TGFβ signaling in the PacMetUT1 model significantly inhibits osteoblastic bone formation and tumor incidence. Thus, TGFβ signaling pathway may be a viable target for the prevention and treatment of prostate cancer-induced bone metastasis.
AuthorsSweta Mishra, Yuping Tang, Long Wang, Linda deGraffenried, I-Tien Yeh, Sherry Werner, Dean Troyer, John A Copland, Lu-Zhe Sun
JournalThe Prostate (Prostate) Vol. 71 Issue 13 Pg. 1441-54 (Sep 15 2011) ISSN: 1097-0045 [Electronic] United States
PMID21321980 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2011 Wiley-Liss, Inc.
Chemical References
  • Smad2 Protein
  • Transforming Growth Factor beta
Topics
  • Animals
  • Base Sequence
  • Bone Neoplasms (prevention & control, secondary)
  • Cell Line, Tumor
  • Cell Proliferation
  • Humans
  • Lung Neoplasms (secondary)
  • Male
  • Mice
  • Middle Aged
  • Molecular Sequence Data
  • Osteoblasts (pathology)
  • Prostatic Neoplasms (pathology)
  • Signal Transduction (physiology)
  • Smad2 Protein (metabolism)
  • Transforming Growth Factor beta (antagonists & inhibitors, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: